Nonetheless, new chances for alleviating the complications of diabetes mellitus are based on sodium–glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists [127,130]. This evidence concerns the gene GLP1R and diabetes mellitus.